Clinical Trial Update: Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating intravenous allopurinol to improve heart function in dilated cardiomyopathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Heart Failure

Drugs mentioned

• Allopurinol (Allopurinol)

Snippet

Sponsor: University of Pennsylvania | Conditions: Cardiovascular Diseases, Cardiomyopathy, Dilated | Phase 1, Phase 2 | Status: WITHDRAWN